| Ytd | -12.69% | |
| 1y | 15.16% |
| Open | 5.09 | Prev Close | 5.09 | Low | 4.98 | High | 5.12 | Mkt Cap | 1.26B |
| Vol | 3.80M | Avg Vol | 4.01M | EPS | -0.21 | P/E | -23.78 | Forward P/E | 40.65 |
| Beta | 0.61 | Short Ratio | 5.41 | Inst. Own | 70.80% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 5.76 | 200-d Avg | 6.03 | 1yr Est | 16.30 |
Ladenburg Thalmann analyst Caroline Palomeque assumes Ardelyx (NASDAQ:ARDX) with a Buy rating and
XPHOZAH is the first and only phosphate absorption inhibitor (PAI) approved by the U.S. Food and Dru
Ardelyx (NASDAQ:ARDX) reported quarterly losses of $(0.15) per share which missed the analyst consen
During Monday's trading, 1214 companies set new 52-week lows.